Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of United Therapeutics Corporation $UTHR

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 9.2% in the 2nd quarter, Holdings Channel reports. The firm owned 4,016 shares of the biotechnology company’s stock after acquiring an additional 338 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in United Therapeutics were worth $1,154,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of UTHR. Lecap Asset Management Ltd. bought a new stake in United Therapeutics in the second quarter worth $667,000. Robeco Institutional Asset Management B.V. boosted its position in shares of United Therapeutics by 3.7% during the second quarter. Robeco Institutional Asset Management B.V. now owns 234,639 shares of the biotechnology company’s stock valued at $67,424,000 after purchasing an additional 8,352 shares in the last quarter. HB Wealth Management LLC boosted its stake in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 35 shares in the last quarter. GraniteShares Advisors LLC boosted its holdings in United Therapeutics by 4.1% in the second quarter. GraniteShares Advisors LLC now owns 1,327 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 52 shares in the last quarter. Finally, Formidable Asset Management LLC lifted its stake in shares of United Therapeutics by 4.9% in the second quarter. Formidable Asset Management LLC now owns 2,060 shares of the biotechnology company’s stock worth $592,000 after buying an additional 97 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 257,935 shares of company stock valued at $103,782,672 over the last three months. 10.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on UTHR. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. HC Wainwright increased their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Jefferies Financial Group upped their price objective on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley lowered their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday. Ten analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $449.57.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $445.38 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48. The company’s 50-day simple moving average is $369.35 and its 200-day simple moving average is $322.73. The stock has a market capitalization of $20.09 billion, a P/E ratio of 17.38, a P/E/G ratio of 6.84 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the firm earned $5.85 earnings per share. The firm’s quarterly revenue was up 11.7% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.